Aristeia Capital’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Aristeia Capital’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-400,000	Closed	-$246K	–	860
2021 Q4	$246K	Hold	400,000	–	–	﹤0.01%	513
2021 Q3	$366K	Hold	400,000	–	–	0.01%	430
2021 Q2	$592K	Buy	+400,000	New	+$349K	0.01%	380

Other funds holding PEARW

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

PSAMP

P. Schoenfeld Asset Management (PSAM) New York $244M AUM 110.95% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Advisory Research Chicago, Illinois $1B AUM 50.12% 1-Year Est. Return

AGC

Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

KCM

Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Aristeia Capital's PEARW Position: Q1 2022 in Review

Aristeia Capital sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q1 2022, closing a stake of 400,000 shares — an estimated $246K sold.

Aristeia Capital first reported a position in PEARW in Q2 2021 and held it in 3 quarters. The position peaked at $592K in Q2 2021. 40 funds tracked by Wall St. Rank hold PEARW as of Q1 2022.

Aristeia Capital reported no remaining Pear Therapeutics, Inc. Warrant position as of Q1 2022 after selling out during the quarter.
Aristeia Capital sold 400,000 Pear Therapeutics, Inc. Warrant shares in Q1 2022, an estimated $246K.
Aristeia Capital first reported a position in Pear Therapeutics, Inc. Warrant in Q2 2021 and held it in 3 quarters.
Aristeia Capital's Pear Therapeutics, Inc. Warrant position peaked at $592K in Q2 2021.
40 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q1 2022.

Based on Aristeia Capital's 13F filing for Q1 2022, filed 16 May 2022.